SCHEMBL3817302

SCHEMBL3817302

Brc1cccc(NN=C(c2ccccc2)c2ccccc2)c1

nearest known ligand 0.57

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 8/20 0.54
KMT2A Q03164 8/20 0.54
LMNA P02545 2/20 0.54
HPGD P15428 2/20 0.54
ALOX12 P18054 1/20 0.54
GAA P10253 3/20 0.49
ALDH1A1 P00352 4/20 0.49
KDM4E B2RXH2 1/20 0.49
SMN1; SMN2 Q16637 5/20 0.45
HTT P42858 1/20 0.45
RAB9A P51151 4/20 0.44
NPC1 O15118 3/20 0.44
CTSL P07711 6/20 0.43
CTSB P07858 1/20 0.43
MAPT P10636 3/20 0.43
TDP1 Q9NUW8 1/20 0.42
C1S P09871 1/20 0.42
TP53 P04637 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12040469 0.82 ALDH1A1 (0.45) MEN1KMT2ALMNAHPGDALOX12
SCHEMBL934433 0.81 GAA (0.61) MEN1KMT2ALMNAHPGDALOX12
SCHEMBL29420498 0.80 MEN1 (0.49) MEN1KMT2ALMNAHPGDALOX12
SCHEMBL31213412 0.79 SMN1; SMN2 (0.54) MEN1KMT2ALMNAHPGDALOX12
SCHEMBL29420504 0.79 MAPT (0.59) MEN1KMT2ALMNAHPGDGAA
SCHEMBL29420482 0.79 SMN1; SMN2 (0.54) MEN1KMT2ALMNAHPGDALOX12
SCHEMBL28294083 0.79 RAB9A (0.54) MEN1KMT2ALMNAHPGDALOX12
SCHEMBL20549105 0.77 RAB9A (0.68) MEN1KMT2ALMNAHPGDALOX12
SCHEMBL23817280 0.76 NPC1 (0.57) MEN1KMT2ALMNAGAAALDH1A1
SCHEMBL2905312 0.76 MAPT (0.53) MEN1KMT2ALMNAGAAALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-114195676-B Biarylhydrazine compound and adduct thereof and application of compound in preparation of antitumor drugs 广州药本君安医药科技股份有限公司 2022-08-05 CN disclosed
CN-114195676-A Biarylhydrazine compound and adduct thereof and application of compound in preparation of antitumor drugs 广州药本君安医药科技股份有限公司 2022-03-18 CN disclosed
US-7595320-B2 Hydrazinocarbonyl-thieno[2,3-C]pyrazoles, process for preparing them, compositions containing them and use thereof AVENTIS PHARMA S.A. (FR) 2009-09-29 US disclosed
EP-1858898-B1 HYDRAZINOCARBONYL-THIENO[2,3-C]PYRAZOLES, PREPARATION METHOD, COMPOSITIONS CONTAINING SAME AND USE AVENTIS PHARMA SA (FR) 2009-08-26 EP disclosed
US-20080146542-A1 Hydrazinocarbonyl-thieno[2,3-C]pyrazoles, Process for Preparing Them, Compositions Containing Them and Use Thereof AVENTIS PHARMA S.A. (FR) 2008-06-19 US disclosed
EP-1858898-A1 HYDRAZINOCARBONYL-THIENO[2,3-C]PYRAZOLES, PREPARATION METHOD, COMPOSITIONS CONTAINING SAME AND USE Aventis Pharma S.A. (FR) 2007-11-28 EP disclosed
WO-2006092510-A1 HYDRAZINOCARBONYL-THIENO[2,3-C]PYRAZOLES, PREPARATION METHOD, COMPOSITIONS CONTAINING SAME AND USE AVENTIS PHARMA S.A. (FR) 2006-09-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080146542-A1 Hydrazinocarbonyl-thieno[2,3-C]pyrazoles, Process for Preparing Them, Compositions Containing Them and Use Thereof TP53, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, CASP3 MEN1 2249/4885KMT2A 2470/4885LMNA 1088/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.